IPI-145 Market Buzz

wpid-IMG_20130905_071816.jpg

Disclosure: I take IPI-145 as part of a phase 1 clinical trial twice each day ;). I have some auto email alerts setup for google to send me about topics of interest and this one recently came to my inbox. The background is financial but the info I found interesting. The investment analysts seem to be excited about the future of this PI3K inhibitor drug under development. The full article is here (free registration req.). Here’s a snippet

Infinity Pharmaceuticals (INFI) is a drug discovery and development company based in Cambridge, MA.

The company’s lead product is IPI-145, being developed for both Hematologic malignancies and Inflammation. Investor’s focus is firmly on IPI-145 and its potential in various types of blood cancer (CLL, iNHL, MCL, T-Cell). IPI-145 is a potent, oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K).

What are PI3Ks?

PI3Ks are a family of enzymes involved in key immune cell functions. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and non-overlapping roles in key cellular functions, including cell proliferation, cell differentiation, cell migration and immunity. Therefore, inhibition of PI3K-delta and PI3K-gamma may have therapeutic potential across a broad range of blood cancers and inflammatory diseases.

IPI-145 is currently being evaluated in a Phase II, open-label study in people with indolent non-Hodgkin lymphoma (INHL), a potentially fatal blood cancer. The expansion portion of a Phase I study of IPI-145 in a broad range of blood cancers is also ongoing. The company is also exploring the potential of IPI-145 in inflammatory diseases. There is an ongoing Phase II-a study in people with mild asthma, and a planned Phase II trial in adults with rheumatoid arthritis.

IPI-145 has shown activity across a broad range of malignancies during Phase I trials

– 68% response rate in iNHL

– 86% PR response and Nodal response in CLL

Yes, you read that right. 86% PR (partial response) and nodal response in CLL.

The data suggests a shorter time to remission and higher overall response rate than Gilead’s new drug idelalisib which recently ended phase 3 clinical trials early and submitted new drug approval (NDA) request to the FDA.

Advertisements

Comments Encouraged

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s